• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Gadolinium should always be used to assess disease activity in MS - Yes.

作者信息

Granziera Cristina, Reich Daniel S

机构信息

Neurologic Clinic and Policlinic, Departments of Medicine, Clinical Research and Biomedical Engineering, University Hospital Basel and University of Basel, Basel, Switzerland/Translational Imaging in Neurology (ThINk) Basel, Department of Medicine and Biomedical Engineering, University Hospital Basel and University of Basel, Basel, Switzerland.

Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NIH), Bethesda, MD, USA.

出版信息

Mult Scler. 2020 Jun;26(7):765-766. doi: 10.1177/1352458520911174. Epub 2020 Jun 2.

DOI:10.1177/1352458520911174
PMID:32484018
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7293550/
Abstract
摘要

相似文献

1
Gadolinium should always be used to assess disease activity in MS - Yes.钆应该始终用于评估多发性硬化症的疾病活动——是的。
Mult Scler. 2020 Jun;26(7):765-766. doi: 10.1177/1352458520911174. Epub 2020 Jun 2.
2
Gadolinium should always be used to assess disease activity in MS - No.钆不应总是用于评估多发性硬化症的疾病活动度——否。
Mult Scler. 2020 Jun;26(7):767-769. doi: 10.1177/1352458520914819. Epub 2020 Jun 2.
3
The benefits and side effects of gadolinium-based contrast agents in multiple sclerosis patients.钆基造影剂在多发性硬化症患者中的益处及副作用。
Rev Assoc Med Bras (1992). 2022 Aug;68(8):979-981. doi: 10.1590/1806-9282.20220643.
4
Free gadolinium is a likely trigger of nephrogenic systemic fibrosis.游离钆可能是引发肾源性系统性纤维化的一个因素。
AJR Am J Roentgenol. 2009 Oct;193(4):W354; author reply W355. doi: 10.2214/AJR.08.2194.
5
Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney and liver disease.钆诱导的肾病和肝病患者的系统性纤维化
Am J Med. 2008 Jan;121(1):e11; author reply e13. doi: 10.1016/j.amjmed.2007.07.030.
6
Gadolinium footprint: Cradle to cradle?钆足迹：从摇篮到摇篮？
J Neuroradiol. 2020 Jun;47(4):247-249. doi: 10.1016/j.neurad.2020.03.006. Epub 2020 Mar 21.
7
Retention of Gadolinium-Based Contrast Agents in Multiple Sclerosis: Retrospective Analysis of an 18-Year Longitudinal Study.钆基造影剂在多发性硬化症中的潴留：一项长达18年的纵向研究的回顾性分析。
AJNR Am J Neuroradiol. 2017 Jul;38(7):1311-1316. doi: 10.3174/ajnr.A5211. Epub 2017 May 11.
8
Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network.肾衰竭患者的钆剂相关性肾源性系统性纤维化：建立跨学科援助网络的必要性
Rheumatology (Oxford). 2010 Apr;49(4):821-3. doi: 10.1093/rheumatology/kep403. Epub 2009 Dec 23.
9
New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions.新的 OFSEP 推荐用于多发性硬化症患者的 MRI 评估：特别考虑钆沉积和频繁采集。
J Neuroradiol. 2020 Jun;47(4):250-258. doi: 10.1016/j.neurad.2020.01.083. Epub 2020 Jan 31.
10
[Use of Gadolinium in Follow-Up MRI of Multiple Sclerosis Patients: Current Recommendations].[钆在多发性硬化症患者随访磁共振成像中的应用：当前建议]
Acta Med Port. 2024 Jan 3;37(1):53-63. doi: 10.20344/amp.20467.

引用本文的文献

1
Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort.多发性硬化症中对比增强病变分割：一种在多中心队列中验证的深度学习方法。
Bioengineering (Basel). 2024 Aug 22;11(8):858. doi: 10.3390/bioengineering11080858.
2
Diffusion-Weighted Images and Contrast-Enhanced MRI in the Diagnosis of Different Stages of Multiple Sclerosis of the Central Nervous System.扩散加权成像和对比增强磁共振成像在中枢神经系统多发性硬化不同阶段诊断中的应用
Cureus. 2023 Jul 10;15(7):e41650. doi: 10.7759/cureus.41650. eCollection 2023 Jul.
3
CNS endothelial derived extracellular vesicles are biomarkers of active disease in multiple sclerosis.中枢神经系统内皮细胞衍生的细胞外囊泡是多发性硬化症活动期的生物标志物。
Fluids Barriers CNS. 2022 Feb 8;19(1):13. doi: 10.1186/s12987-021-00299-4.

本文引用的文献

1
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.接受 II 类钆基造影剂的 4 或 5 期慢性肾脏病患者发生肾源性系统纤维化的风险：系统评价和荟萃分析。
JAMA Intern Med. 2020 Feb 1;180(2):223-230. doi: 10.1001/jamainternmed.2019.5284.
2
Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines.多发性硬化症磁共振成像病变评估：实用指南。
Brain. 2019 Jul 1;142(7):1858-1875. doi: 10.1093/brain/awz144.
3
The current role of MRI in differentiating multiple sclerosis from its imaging mimics.磁共振成像在鉴别多发性硬化与其影像模拟疾病中的当前作用。
Nat Rev Neurol. 2018 Mar 20;14(4):213. doi: 10.1038/nrneurol.2018.39.
4
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.ECTRIMS/EAN 多发性硬化症药物治疗指南
Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20.
5
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.多发性硬化症的诊断：2017 年麦当劳标准修订版。
Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21.
6
The Use of Noncontrast Quantitative MRI to Detect Gadolinium-Enhancing Multiple Sclerosis Brain Lesions: A Systematic Review and Meta-Analysis.使用非对比定量磁共振成像检测钆增强型多发性硬化症脑损伤：系统评价与荟萃分析
AJNR Am J Neuroradiol. 2017 Jul;38(7):1317-1322. doi: 10.3174/ajnr.A5209. Epub 2017 May 18.
7
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.循证指南：磁共振成像在多发性硬化中的应用——建立疾病预后和监测患者的 MAGNIMS 共识指南。
Nat Rev Neurol. 2015 Oct;11(10):597-606. doi: 10.1038/nrneurol.2015.157. Epub 2015 Sep 15.
8
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.基于钆的磁共振成像对多发性硬化软脑膜炎症的特征分析
Neurology. 2015 Jul 7;85(1):18-28. doi: 10.1212/WNL.0000000000001587. Epub 2015 Apr 17.
9
Predicting breakdown of the blood-brain barrier in multiple sclerosis without contrast agents.预测多发性硬化症中无造影剂的血脑屏障破裂。
AJNR Am J Neuroradiol. 2012 Sep;33(8):1586-90. doi: 10.3174/ajnr.A2997. Epub 2012 Mar 22.